G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022

Rhea-AI Summary

G1 Therapeutics, Inc. (GTHX) announced a webcast and conference call for a corporate and financial update on May 4, 2022, at 8:30 a.m. ET. The event will provide insights into the company's first quarter performance. G1 Therapeutics focuses on developing therapies for cancer and is known for its product, COSELA (trilaciclib). The call can be accessed through a dedicated phone line and will also be available via a webcast on the company's website, ensuring transparency with investors.

Positive

• Company is hosting a corporate and financial update call, indicating transparency and engagement with investors.
• G1's focus on developing cancer therapies and having a commercial product, COSELA, shows potential for growth.

Negative

• None.

RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2022 on Wednesday, May 4, 2022 at 8:30 a.m. ET.

The live call may be accessed by dialing (866) 763-6020 (domestic) or (409) 216-0626 (international) and entering the conference code: 2229795. The live and archived webcast will be available on the Events & Presentations page of http://www.g1therapeutics.com.

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

G1 Therapeutics™ and the G1 Therapeutics logo are trademarks of G1 Therapeutics, Inc.

G1 Therapeutics Contacts:

Will Roberts
Vice President
Investor Relations and Corporate Communications
(919) 907-1944
wroberts@g1therapeutics.com

Rebecca Levine
Director, Corporate Communications and Public Relations
(919) 667-8711
rlevine@g1therapeutics.com  

FAQ

What is G1 Therapeutics' upcoming financial update about?

G1 Therapeutics will provide a corporate and financial update during a webcast on May 4, 2022, at 8:30 a.m. ET.

How can I access GTHX's conference call?

You can access the conference call by dialing (866) 763-6020 for domestic calls or (409) 216-0626 for international calls, using the conference code 2229795.

What is COSELA and why is it significant for GTHX?

COSELA (trilaciclib) is G1 Therapeutics' first commercial product, focused on improving the lives of cancer patients.

Where can I find the webcast of G1 Therapeutics' financial update?

The webcast will be available on the Events & Presentations page of G1 Therapeutics' website.